APO Research
Talk to an analyst

APO RESEARCH · REPORT

Restless Legs Syndrome

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Restless Legs Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025198 pages

Choose your research edition.

Industry ResearchRestless Legs Syndrome Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Restless Legs Syndrome Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Restless Legs Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Restless Legs Syndrome Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Restless Legs Syndrome Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Restless Legs Syndrome market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Restless Legs Syndrome include UCB SA, Omeros Corporation, Manhattan Pharmaceuticals, Ligand Pharmaceuticals Incorporated, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., GlaxoSmithKline plc., Boehringer Ingelheim GmbH and axxonis Pharma AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Restless Legs Syndrome market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Restless Legs Syndrome and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Restless Legs Syndrome revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Restless Legs Syndrome market size, projected growth trends, production technologies, key applications, and end-use industries.

Restless Legs Syndrome Segment by Company

UCB SA

Omeros Corporation

Manhattan Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Kyowa Hakko Kirin Co.

Jazz Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Boehringer Ingelheim GmbH

axxonis Pharma AG

Astellas

Arbor Pharmaceuticals

Restless Legs Syndrome Segment by Type

Pharmacological Therapy

Non-Pharmacological Therapy

Restless Legs Syndrome Segment by Application

Above 50 Years Old

Below 35 Years Old

From 35 to 50 Years Old

Restless Legs Syndrome Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Restless Legs Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Restless Legs Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Restless Legs Syndrome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Restless Legs Syndrome in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Restless Legs Syndrome industry.

Chapter 3: Detailed analysis of Restless Legs Syndrome companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Restless Legs Syndromerevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Restless Legs Syndrome Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Pharmacological Therapy Table 3. Key Players of Non-Pharmacological Therapy Table 4. Global Restless Legs Syndrome Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Above 50 Years Old Table 6. Key Players of Below 35 Years Old Table 7. Key Players of From 35 to 50 Years Old Table 8. Global Restless Legs Syndrome Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Restless Legs Syndrome Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Restless Legs Syndrome Market Share by Region (2021-2026) Table 11. Global Restless Legs Syndrome Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Restless Legs Syndrome Market Share by Region (2027-2032) Table 13. Restless Legs Syndrome Industry Trends Table 14. Restless Legs Syndrome Industry Drivers Table 15. Restless Legs Syndrome Industry Opportunities and Challenges Table 16. Restless Legs Syndrome Industry Restraints Table 17. Global Restless Legs Syndrome Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Restless Legs Syndrome Revenue Market Share by Company (2021-2026) Table 19. Global Restless Legs Syndrome Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Restless Legs Syndrome Key Company Head Office and Area Served Table 21. Global Restless Legs Syndrome Company, Product Type & Application Table 22. Global Restless Legs Syndrome Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Restless Legs Syndrome by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Restless Legs Syndrome Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Restless Legs Syndrome Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Restless Legs Syndrome Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Restless Legs Syndrome Revenue Market Share by Type (2021-2026) Table 29. Global Restless Legs Syndrome Revenue Market Share by Type (2027-2032) Table 30. Global Restless Legs Syndrome Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Restless Legs Syndrome Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Restless Legs Syndrome Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Restless Legs Syndrome Revenue Market Share by Application (2021-2026) Table 34. Global Restless Legs Syndrome Revenue Market Share by Application (2027-2032) Table 35. UCB SA Company Information Table 36. UCB SA Business Overview Table 37. UCB SA Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. UCB SA Restless Legs Syndrome Product Portfolio Table 39. UCB SA Recent Development Table 40. Omeros Corporation Company Information Table 41. Omeros Corporation Business Overview Table 42. Omeros Corporation Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Omeros Corporation Restless Legs Syndrome Product Portfolio Table 44. Omeros Corporation Recent Development Table 45. Manhattan Pharmaceuticals Company Information Table 46. Manhattan Pharmaceuticals Business Overview Table 47. Manhattan Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio Table 49. Manhattan Pharmaceuticals Recent Development Table 50. Ligand Pharmaceuticals Incorporated Company Information Table 51. Ligand Pharmaceuticals Incorporated Business Overview Table 52. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio Table 54. Ligand Pharmaceuticals Incorporated Recent Development Table 55. Kyowa Hakko Kirin Co. Company Information Table 56. Kyowa Hakko Kirin Co. Business Overview Table 57. Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio Table 59. Kyowa Hakko Kirin Co. Recent Development Table 60. Jazz Pharmaceuticals, Inc. Company Information Table 61. Jazz Pharmaceuticals, Inc. Business Overview Table 62. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio Table 64. Jazz Pharmaceuticals, Inc. Recent Development Table 65. GlaxoSmithKline plc. Company Information Table 66. GlaxoSmithKline plc. Business Overview Table 67. GlaxoSmithKline plc. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio Table 69. GlaxoSmithKline plc. Recent Development Table 70. Boehringer Ingelheim GmbH Company Information Table 71. Boehringer Ingelheim GmbH Business Overview Table 72. Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio Table 74. Boehringer Ingelheim GmbH Recent Development Table 75. axxonis Pharma AG Company Information Table 76. axxonis Pharma AG Business Overview Table 77. axxonis Pharma AG Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. axxonis Pharma AG Restless Legs Syndrome Product Portfolio Table 79. axxonis Pharma AG Recent Development Table 80. Astellas Company Information Table 81. Astellas Business Overview Table 82. Astellas Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Astellas Restless Legs Syndrome Product Portfolio Table 84. Astellas Recent Development Table 85. Arbor Pharmaceuticals Company Information Table 86. Arbor Pharmaceuticals Business Overview Table 87. Arbor Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio Table 89. Arbor Pharmaceuticals Recent Development Table 90. North America Restless Legs Syndrome Market Size by Type (2021-2026) & (US$ Million) Table 91. North America Restless Legs Syndrome Market Size by Type (2027-2032) & (US$ Million) Table 92. North America Restless Legs Syndrome Market Size by Application (2021-2026) & (US$ Million) Table 93. North America Restless Legs Syndrome Market Size by Application (2027-2032) & (US$ Million) Table 94. North America Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Restless Legs Syndrome Market Size by Country (2021-2026) Table 96. North America Restless Legs Syndrome Market Size by Country (2027-2032) Table 97. Europe Restless Legs Syndrome Market Size by Type (2021-2026) & (US$ Million) Table 98. Europe Restless Legs Syndrome Market Size by Type (2027-2032) & (US$ Million) Table 99. Europe Restless Legs Syndrome Market Size by Application (2021-2026) & (US$ Million) Table 100. Europe Restless Legs Syndrome Market Size by Application (2027-2032) & (US$ Million) Table 101. Europe Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Restless Legs Syndrome Market Size by Country (2021-2026) Table 103. Europe Restless Legs Syndrome Market Size by Country (2027-2032) Table 104. China Restless Legs Syndrome Market Size by Type (2021-2026) & (US$ Million) Table 105. China Restless Legs Syndrome Market Size by Type (2027-2032) & (US$ Million) Table 106. China Restless Legs Syndrome Market Size by Application (2021-2026) & (US$ Million) Table 107. China Restless Legs Syndrome Market Size by Application (2027-2032) & (US$ Million) Table 108. Asia Restless Legs Syndrome Market Size by Type (2021-2026) & (US$ Million) Table 109. Asia Restless Legs Syndrome Market Size by Type (2027-2032) & (US$ Million) Table 110. Asia Restless Legs Syndrome Market Size by Application (2021-2026) & (US$ Million) Table 111. Asia Restless Legs Syndrome Market Size by Application (2027-2032) & (US$ Million) Table 112. Asia Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Restless Legs Syndrome Market Size by Country (2021-2026) Table 114. Asia Restless Legs Syndrome Market Size by Country (2027-2032) Table 115. South America, Middle East & Africa Restless Legs Syndrome Market Size by Type (2021-2026) & (US$ Million) Table 116. South America, Middle East & Africa Restless Legs Syndrome Market Size by Type (2027-2032) & (US$ Million) Table 117. South America, Middle East & Africa Restless Legs Syndrome Market Size by Application (2021-2026) & (US$ Million) Table 118. South America, Middle East & Africa Restless Legs Syndrome Market Size by Application (2027-2032) & (US$ Million) Table 119. South America, Middle East & Africa Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. South America, Middle East & Africa Restless Legs Syndrome Market Size by Country (2021-2026) Table 121. South America, Middle East & Africa Restless Legs Syndrome Market Size by Country (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Restless Legs Syndrome Product Image Figure 2. Global Restless Legs Syndrome Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Restless Legs Syndrome Market Share by Type: 2025 VS 2032 Figure 4. Pharmacological Therapy Image Figure 5. Non-Pharmacological Therapy Image Figure 6. Global Restless Legs Syndrome Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Restless Legs Syndrome Market Share by Application: 2025 VS 2032 Figure 8. Above 50 Years Old Image Figure 9. Below 35 Years Old Image Figure 10. From 35 to 50 Years Old Image Figure 11. Global Restless Legs Syndrome Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 13. Global Restless Legs Syndrome Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Restless Legs Syndrome Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Restless Legs Syndrome Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Restless Legs Syndrome Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Restless Legs Syndrome Revenue Market Share by Type (2021-2032) Figure 20. Global Restless Legs Syndrome Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Restless Legs Syndrome Revenue Market Share by Application (2021-2032) Figure 22. North America Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 23. North America Restless Legs Syndrome Market Share by Type (2021-2032) Figure 24. North America Restless Legs Syndrome Market Share by Application (2021-2032) Figure 25. North America Restless Legs Syndrome Market Share by Country (2021-2032) Figure 26. United States Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 27. Canada Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 29. Europe Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 30. Europe Restless Legs Syndrome Market Share by Type (2021-2032) Figure 31. Europe Restless Legs Syndrome Market Share by Application (2021-2032) Figure 32. Europe Restless Legs Syndrome Market Share by Country (2021-2032) Figure 33. Germany Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 34. France Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 36. Italy Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 37. Russia Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 39. China Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 40. China Restless Legs Syndrome Market Share by Type (2021-2032) Figure 41. China Restless Legs Syndrome Market Share by Application (2021-2032) Figure 42. Asia Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 43. Asia Restless Legs Syndrome Market Share by Type (2021-2032) Figure 44. Asia Restless Legs Syndrome Market Share by Application (2021-2032) Figure 45. Asia Restless Legs Syndrome Market Share by Country (2021-2032) Figure 46. Japan Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 50. India Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 51. Australia Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Restless Legs Syndrome Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Restless Legs Syndrome Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Restless Legs Syndrome Market Share by Country (2021-2032) Figure 56. Brazil Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 61. UAE Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 63. Chile Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Pharmacological Therapy
  • Non-Pharmacological Therapy
Applications
  • Above 50 Years Old
  • Below 35 Years Old
  • From 35 to 50 Years Old
Companies covered
  • UCB SA
  • Omeros Corporation
  • Manhattan Pharmaceuticals
  • Ligand Pharmaceuticals Incorporated
  • Kyowa Hakko Kirin Co.
  • Jazz Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Boehringer Ingelheim GmbH
  • axxonis Pharma AG
  • Astellas
  • Arbor Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Restless Legs Syndrome Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Pharmacological Therapy
  5. 1.2.3 Non-Pharmacological Therapy
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Restless Legs Syndrome Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Above 50 Years Old
  9. 1.3.3 Below 35 Years Old
  10. 1.3.4 From 35 to 50 Years Old
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Restless Legs Syndrome Growth Trends by Region
  13. 1.5.1 Global Restless Legs Syndrome Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Restless Legs Syndrome Market Size by Region (2021-2026)
  15. 1.5.3 Restless Legs Syndrome Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Restless Legs Syndrome Market Dynamics
  1. 2.1 Restless Legs Syndrome Industry Trends
  2. 2.2 Restless Legs Syndrome Industry Drivers
  3. 2.3 Restless Legs Syndrome Industry Opportunities and Challenges
  4. 2.4 Restless Legs Syndrome Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Restless Legs Syndrome Revenue by Company (2021-2026)
  2. 3.2 Global Restless Legs Syndrome Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Restless Legs Syndrome Key Company Head office and Area Served
  4. 3.4 Global Restless Legs Syndrome Company, Product Type & Application
  5. 3.5 Global Restless Legs Syndrome Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Restless Legs Syndrome Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Restless Legs Syndrome Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Restless Legs Syndrome Tier 1, Tier 2, and Tier 3
4 Restless Legs Syndrome Market by Type
  1. 4.1 Global Restless Legs Syndrome Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Restless Legs Syndrome Market Size by Type (2021-2032)
  3. 4.3 Global Restless Legs Syndrome Market Size Share by Type (2021-2032)
5 Restless Legs Syndrome Market by Application
  1. 5.1 Global Restless Legs Syndrome Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Restless Legs Syndrome Market Size by Application (2021-2032)
  3. 5.3 Global Restless Legs Syndrome Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 UCB SA
  2. 6.1.1 UCB SA Company Information
  3. 6.1.2 UCB SA Business Overview
  4. 6.1.3 UCB SA Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 UCB SA Restless Legs Syndrome Product Portfolio
  6. 6.1.5 UCB SA Recent Developments
  7. 6.2 Omeros Corporation
  8. 6.2.1 Omeros Corporation Company Information
  9. 6.2.2 Omeros Corporation Business Overview
  10. 6.2.3 Omeros Corporation Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Omeros Corporation Restless Legs Syndrome Product Portfolio
  12. 6.2.5 Omeros Corporation Recent Developments
  13. 6.3 Manhattan Pharmaceuticals
  14. 6.3.1 Manhattan Pharmaceuticals Company Information
  15. 6.3.2 Manhattan Pharmaceuticals Business Overview
  16. 6.3.3 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio
  18. 6.3.5 Manhattan Pharmaceuticals Recent Developments
  19. 6.4 Ligand Pharmaceuticals Incorporated
  20. 6.4.1 Ligand Pharmaceuticals Incorporated Company Information
  21. 6.4.2 Ligand Pharmaceuticals Incorporated Business Overview
  22. 6.4.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio
  24. 6.4.5 Ligand Pharmaceuticals Incorporated Recent Developments
  25. 6.5 Kyowa Hakko Kirin Co.
  26. 6.5.1 Kyowa Hakko Kirin Co. Company Information
  27. 6.5.2 Kyowa Hakko Kirin Co. Business Overview
  28. 6.5.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio
  30. 6.5.5 Kyowa Hakko Kirin Co. Recent Developments
  31. 6.6 Jazz Pharmaceuticals, Inc.
  32. 6.6.1 Jazz Pharmaceuticals, Inc. Company Information
  33. 6.6.2 Jazz Pharmaceuticals, Inc. Business Overview
  34. 6.6.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio
  36. 6.6.5 Jazz Pharmaceuticals, Inc. Recent Developments
  37. 6.7 GlaxoSmithKline plc.
  38. 6.7.1 GlaxoSmithKline plc. Company Information
  39. 6.7.2 GlaxoSmithKline plc. Business Overview
  40. 6.7.3 GlaxoSmithKline plc. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio
  42. 6.7.5 GlaxoSmithKline plc. Recent Developments
  43. 6.8 Boehringer Ingelheim GmbH
  44. 6.8.1 Boehringer Ingelheim GmbH Company Information
  45. 6.8.2 Boehringer Ingelheim GmbH Business Overview
  46. 6.8.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio
  48. 6.8.5 Boehringer Ingelheim GmbH Recent Developments
  49. 6.9 axxonis Pharma AG
  50. 6.9.1 axxonis Pharma AG Company Information
  51. 6.9.2 axxonis Pharma AG Business Overview
  52. 6.9.3 axxonis Pharma AG Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 axxonis Pharma AG Restless Legs Syndrome Product Portfolio
  54. 6.9.5 axxonis Pharma AG Recent Developments
  55. 6.10 Astellas
  56. 6.10.1 Astellas Company Information
  57. 6.10.2 Astellas Business Overview
  58. 6.10.3 Astellas Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Astellas Restless Legs Syndrome Product Portfolio
  60. 6.10.5 Astellas Recent Developments
  61. 6.11 Arbor Pharmaceuticals
  62. 6.11.1 Arbor Pharmaceuticals Company Information
  63. 6.11.2 Arbor Pharmaceuticals Business Overview
  64. 6.11.3 Arbor Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio
  66. 6.11.5 Arbor Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Restless Legs Syndrome Market Size (2021-2032)
  2. 7.2 North America Restless Legs Syndrome Market Size by Type
  3. 7.2.1 North America Restless Legs Syndrome Market Size by Type (2021-2026)
  4. 7.2.2 North America Restless Legs Syndrome Market Size by Type (2027-2032)
  5. 7.2.3 North America Restless Legs Syndrome Market Share by Type (2021-2032)
  6. 7.3 North America Restless Legs Syndrome Market Size by Application
  7. 7.3.1 North America Restless Legs Syndrome Market Size by Application (2021-2026)
  8. 7.3.2 North America Restless Legs Syndrome Market Size by Application (2027-2032)
  9. 7.3.3 North America Restless Legs Syndrome Market Share by Application (2021-2032)
  10. 7.4 North America Restless Legs Syndrome Market Size by Country
  11. 7.4.1 North America Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Restless Legs Syndrome Market Size by Country (2021-2026)
  13. 7.4.3 North America Restless Legs Syndrome Market Size by Country (2027-2032)
  14. 7.4.4 North America Restless Legs Syndrome Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Restless Legs Syndrome Market Size (2021-2032)
  2. 8.2 Europe Restless Legs Syndrome Market Size by Type
  3. 8.2.1 Europe Restless Legs Syndrome Market Size by Type (2021-2026)
  4. 8.2.2 Europe Restless Legs Syndrome Market Size by Type (2027-2032)
  5. 8.2.3 Europe Restless Legs Syndrome Market Share by Type (2021-2032)
  6. 8.3 Europe Restless Legs Syndrome Market Size by Application
  7. 8.3.1 Europe Restless Legs Syndrome Market Size by Application (2021-2026)
  8. 8.3.2 Europe Restless Legs Syndrome Market Size by Application (2027-2032)
  9. 8.3.3 Europe Restless Legs Syndrome Market Share by Application (2021-2032)
  10. 8.4 Europe Restless Legs Syndrome Market Size by Country
  11. 8.4.1 Europe Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Restless Legs Syndrome Market Size by Country (2021-2026)
  13. 8.4.3 Europe Restless Legs Syndrome Market Size by Country (2027-2032)
  14. 8.4.4 Europe Restless Legs Syndrome Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Restless Legs Syndrome Market Size (2021-2032)
  2. 9.2 China Restless Legs Syndrome Market Size by Type
  3. 9.2.1 China Restless Legs Syndrome Market Size by Type (2021-2026)
  4. 9.2.2 China Restless Legs Syndrome Market Size by Type (2027-2032)
  5. 9.2.3 China Restless Legs Syndrome Market Share by Type (2021-2032)
  6. 9.3 China Restless Legs Syndrome Market Size by Application
  7. 9.3.1 China Restless Legs Syndrome Market Size by Application (2021-2026)
  8. 9.3.2 China Restless Legs Syndrome Market Size by Application (2027-2032)
  9. 9.3.3 China Restless Legs Syndrome Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Restless Legs Syndrome Market Size (2021-2032)
  2. 10.2 Asia Restless Legs Syndrome Market Size by Type
  3. 10.2.1 Asia Restless Legs Syndrome Market Size by Type (2021-2026)
  4. 10.2.2 Asia Restless Legs Syndrome Market Size by Type (2027-2032)
  5. 10.2.3 Asia Restless Legs Syndrome Market Share by Type (2021-2032)
  6. 10.3 Asia Restless Legs Syndrome Market Size by Application
  7. 10.3.1 Asia Restless Legs Syndrome Market Size by Application (2021-2026)
  8. 10.3.2 Asia Restless Legs Syndrome Market Size by Application (2027-2032)
  9. 10.3.3 Asia Restless Legs Syndrome Market Share by Application (2021-2032)
  10. 10.4 Asia Restless Legs Syndrome Market Size by Country
  11. 10.4.1 Asia Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Restless Legs Syndrome Market Size by Country (2021-2026)
  13. 10.4.3 Asia Restless Legs Syndrome Market Size by Country (2027-2032)
  14. 10.4.4 Asia Restless Legs Syndrome Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Restless Legs Syndrome Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Restless Legs Syndrome Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Restless Legs Syndrome Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Restless Legs Syndrome Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Restless Legs Syndrome Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Restless Legs Syndrome Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Restless Legs Syndrome Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Restless Legs Syndrome Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Restless Legs Syndrome Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Restless Legs Syndrome Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Restless Legs Syndrome Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Restless Legs Syndrome Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Restless Legs Syndrome Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Restless Legs Syndrome Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst